Phase 2 COSMOS Study Results Published in The Lancet Demonstrate Efficacy and Safety of Janssen’s Once-Daily Simeprevir in All Oral 12-Week Combination with Sofosbuvir for Genotype 1 Chronic Hepatitis C
- EMEA Innovative Medicine
- Phase 2 COSMOS Study Results Published on Efficacy and Safety of Simeprevir
Phase 2 COSMOS Study Results Published on Efficacy and Safety of Simeprevir
- X (Twitter)
Copy link